DSSG Group: Skin Cancer

with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin.

The purpose of this study is that there is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.

with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

The purpose of this study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a “study drug” or called “study drugs” when combined). The study is focused on patients with a type of skin cancer known as melanoma.

Either stage IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected.

The purpose of this study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by relapse free survival (RFS).

Cutaneous Squamous Cell Carcinoma (High Risk)

The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).